Therefore, even individuals without childhood eczema may experience it later in life. Dr Grant has debunked the common ...

There are lots of misconceptions around eczema, from poor hygiene to the skin condition disappearing on its own - there is a ...

"This strategic transaction brings together Biosion's and Aclaris' innovative programs with Aclaris' development capabilities ...

ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitisZORYVE, a next-generation topical phosphodiesterase-4 ...

The following is a summary of “Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced that the first subject has been dosed in ...

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

Whatever TikTok trends or buzzy skin-care ingredients are out there, heed this piece of advice: Don't compromise your barrier ...

BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.

Continued execution across all programs, including positive results up to nine months from APG777 Phase 1 trial that continue to support potential best-in-class profile On track to report Phase 2 Part ...

Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing. See why I rate APGE stock ...

Tralokinumab is approved for the treatment of adults with moderate-to-severe atopic dermatitis in the EU, UK, Canada, United Arab Emirates, and Switzerland. It is also approved for adults in the ...